NorthWest Biotherapeutics Inc (NWBO)

[longusa]

The abstract was confusing to me. The intro sentence seemed to suggest that deficient gene methylation led to greater chemo sensitivity, yet the results were that patients with gene methylation had better results????

Just looking at the results stated, though, the risk I think f3 brings up is that the more the placebo group has methylated gene patients in it, the longer the PFS and OS the placebo group will show. Did I get that right, f3?

My take is that neither the Phase I or Phase III trials had selection criteria on methylation, so the share of methylated patients should be approx. the same in the treatment vs placebo arms. The result in my thinking is that the greater the gene methylation in the patient population, the longer in time it would take for an advantage to show up for DCVax-L.

This would be another area where the 33 patients from 2006-2008 could play a key role, as that should hopefully be a long enough time to show an advantage even for methylated gene patients.